Human artificial oocytes from patients' somatic cells: past, present and future.

Reproduction & Fertility Pub Date : 2021-01-05 eCollection Date: 2021-01-01 DOI:10.1530/RAF-20-0039
Jan Tesarik, Carmen Mendoza, Raquel Mendoza-Tesarik
{"title":"Human artificial oocytes from patients' somatic cells: past, present and future.","authors":"Jan Tesarik,&nbsp;Carmen Mendoza,&nbsp;Raquel Mendoza-Tesarik","doi":"10.1530/RAF-20-0039","DOIUrl":null,"url":null,"abstract":"<p><p>The first attempts at generating functional human oocytes by using the transfer of patients' somatic cell nuclei, as DNA source, into donor enucleated oocytes date back to the early 2000s. After initial attempts, that gave rather encouraging results, the technique was abandoned because of adverse results with this technique in the mouse model. Priority was then given to the use of induced pluripotent stem (iPS) cells, based on excellent results in the mouse, where mature oocytes and live healthy offspring were achieved. However, these results could not be reproduced in humans, and oogenesis with human iPS cells did not continue beyond the stage of oogonium. These data suggest that the use of enucleated donor oocytes will be necessary to achieve fertilizable human oocytes with somatic cell-derived DNA. The main problem of all these techniques is that they have to meet with two, sometimes contradictory, requirements: the haploidization of somatic cell-derived DNA, on the one hand, and the remodeling/reprogramming of DNA of somatic cell origin, so as to be capable of supporting all stages of preimplantation and postimplantation development and to give rise to all cell types of the future organism. Further research is needed to determine the optimal strategy to cope with these two requirements.</p><p><strong>Lay summary: </strong>The recourse to artificial oocytes, generated by using the patient's own DNA derived from cells of somatic origin, represents the ultimate opportunity for women who lack healthy oocytes of their own but yearn for genetically related offspring. Many different pathologies, such as ovarian cancer, premature ovarian failure, other ovarian diseases and natural, age-related ovarian decay can cause the absence of available oocytes. The demand for artificial oocytes is increasing continuously, mainly because of the tendency to postpone maternity to still more advanced ages, when the quantity and quality of oocytes is low. This minireview focuses on the generation of artificial oocytes using different strategies and scenarios, based on the accumulated experience in humans and experimental animals.</p>","PeriodicalId":21128,"journal":{"name":"Reproduction & Fertility","volume":"2 1","pages":"H1-H8"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812406/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproduction & Fertility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/RAF-20-0039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The first attempts at generating functional human oocytes by using the transfer of patients' somatic cell nuclei, as DNA source, into donor enucleated oocytes date back to the early 2000s. After initial attempts, that gave rather encouraging results, the technique was abandoned because of adverse results with this technique in the mouse model. Priority was then given to the use of induced pluripotent stem (iPS) cells, based on excellent results in the mouse, where mature oocytes and live healthy offspring were achieved. However, these results could not be reproduced in humans, and oogenesis with human iPS cells did not continue beyond the stage of oogonium. These data suggest that the use of enucleated donor oocytes will be necessary to achieve fertilizable human oocytes with somatic cell-derived DNA. The main problem of all these techniques is that they have to meet with two, sometimes contradictory, requirements: the haploidization of somatic cell-derived DNA, on the one hand, and the remodeling/reprogramming of DNA of somatic cell origin, so as to be capable of supporting all stages of preimplantation and postimplantation development and to give rise to all cell types of the future organism. Further research is needed to determine the optimal strategy to cope with these two requirements.

Lay summary: The recourse to artificial oocytes, generated by using the patient's own DNA derived from cells of somatic origin, represents the ultimate opportunity for women who lack healthy oocytes of their own but yearn for genetically related offspring. Many different pathologies, such as ovarian cancer, premature ovarian failure, other ovarian diseases and natural, age-related ovarian decay can cause the absence of available oocytes. The demand for artificial oocytes is increasing continuously, mainly because of the tendency to postpone maternity to still more advanced ages, when the quantity and quality of oocytes is low. This minireview focuses on the generation of artificial oocytes using different strategies and scenarios, based on the accumulated experience in humans and experimental animals.

Abstract Image

Abstract Image

Abstract Image

从病人体细胞提取人类人工卵母细胞:过去、现在和未来。
通过将患者体细胞细胞核作为DNA来源转移到供体去核卵母细胞中来产生功能性人类卵母细胞的首次尝试可以追溯到21世纪初。最初的尝试取得了令人鼓舞的结果,但由于该技术在小鼠模型中的不良结果,该技术被放弃了。然后,基于在小鼠身上取得的优异结果,优先考虑使用诱导多能干细胞(iPS),在小鼠身上获得了成熟的卵母细胞和健康的活的后代。然而,这些结果不能在人类中复制,并且人类iPS细胞的卵子发生不能持续到卵原体阶段。这些数据表明,使用去核的供体卵母细胞将是必要的,以获得具有体细胞来源DNA的可受精的人类卵母细胞。所有这些技术的主要问题是,它们必须满足两个有时相互矛盾的要求:一方面是体细胞来源DNA的单倍体化,另一方面是体细胞来源DNA的重塑/重编程,以便能够支持着床前和着床后发育的所有阶段,并产生未来生物体的所有细胞类型。需要进一步的研究来确定应对这两个要求的最佳策略。总结:利用患者自身体细胞DNA生成的人工卵母细胞,为自身缺乏健康卵母细胞但渴望有基因相关后代的女性提供了最终机会。许多不同的病理,如卵巢癌、卵巢早衰、其他卵巢疾病和自然的、与年龄相关的卵巢衰退,都可能导致可用卵母细胞的缺失。对人工卵母细胞的需求在不断增加,主要是由于人们倾向于将生育推迟到更高龄,而此时卵母细胞的数量和质量都较低。本文基于人类和实验动物积累的经验,重点介绍了不同策略和情况下人工卵母细胞的生成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信